Dados B3 › TAEE3 × AXIA3
TAEE3 × AXIA3
Indicators
Each row uses the most recent year in which BOTH companies have the figure, and says which year that is. A cell with ! carries a caveat — hover to read it. We do not name a winner: that would be a recommendation, and this site does not give any.
| indicator | TAEE3 | AXIA3 | year |
|---|---|---|---|
| ROE | 21.7% | 5.5% | 2025 |
| ROIC | 15.0% | 1.6%! | 2025 |
| ROA | 7.4% | 2.3% | 2025 |
| Gross margin | 55.1% | 42.9% | 2025 |
| EBIT margin | 59.2% | 9.6% | 2025 |
| Net margin | 34.2% | 15.9% | 2025 |
| Net debt/EBITDA | 3.66x | 5.48x | 2025 |
| Current ratio | 1.57x | 1.68x | 2025 |
| Revenue growth (1y) | 24.4% | 2.7% | 2025 |
| Revenue growth (5y CAGR) | 5.4% | 7.3% | 2025 |
| Piotroski F-Score | 5/9 | 4/9 | 2025 |
Point-in-time multiples
Priced at the first session on or after the day each filing became public — never the period close.
| indicator | TAEE3 | AXIA3 | year |
|---|---|---|---|
| P/E | 9.14x | 27.24x | 2025 |
| P/B | 1.90x | 1.51x | 2025 |
| EV/EBITDA | 8.81x | 26.44x | 2025 |
| FCF yield | 10.3% | 6.7% | 2025 |
Numbers on this page are live. Data version 2026-09-01-supressao-declarada · page generated 2026-09-09 13:38 UTC. If this does not match /saude, you are reading a cached copy.
Sources: CVM (open data, ODbL) and B3 (COTAHIST). Not affiliated with B3 or the CVM. Not investment advice.